The Asia Pacific Veterinary Biomarkers Market would witness market growth of 12.6% CAGR during the forecast period (2022-2028).
Making decisions on urgent treatment can be hampered by conventional dependence on the conventional "pipeline," in which samples are sent to centralized laboratories and test findings are transmitted to vets. It is suggested that newer diagnostic techniques could provide faster, more accurate, and less expensive results.
Concern over the inappropriate use of antibiotics to treat animal disease is growing, and there is a strong movement toward more evidence-based veterinary treatment. As a result, diagnostic tests are receiving more attention as crucial justifiers of treatment choices, particularly with regard to the use of antibiotics. This can be seen in the growing adoption of required diagnostic tests by assurance and certificate programs for the deployment of critically needed antibiotics.
The adoption of modern test methods that produce results efficiently and decisively, such as immunological & molecular diagnostics, hematology, and nanotechnology, is further boosting the rise. Nucleic acids, non-PCR procedures, biosensors, fluorescence polarisation technology, whole-genome sequencing (WGS), biomarkers, wearables, and apps like Vet on Demand, Treat, and Pet Life are some of the upcoming technologies and approaches in the veterinary biomarkers industry.
Emerging economies in the Asia-Pacific region have enticed prospects for businesses engaged in veterinary immunodiagnostics. The region has witnessed the emergence of veterinary services into a major business. Services for animals have changed, and they now need to reflect current social, economic, and political conditions. Prediction, prevention, and treatment of animal disease are becoming more and more significant throughout Asia, with China and Japan continuing to set the pace. Thailand, India, Indonesia, Vietnam, Singapore, South Korea, and Malaysia are other developing markets.
The China market dominated the Asia Pacific Veterinary Biomarkers Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $125.5 million by 2028. The Japan market is estimated to grow a CAGR of 11.9% during (2022 - 2028). Additionally, The India market would experience a CAGR of 13.3% during (2022 - 2028).
Based on Animal Type, the market is segmented into Companion (Dogs, Cats, and Others) and Production. Based on Disease Type, the market is segmented into Inflammatory & Infectious Diseases, Turf & Landscaping, Tumor, Skeletal Muscle Diseases, and Others. Based on Product Type, the market is segmented into Biomarkers, Kits & Reagents and Biomarker Readers. Based on Application, the market is segmented into Disease Diagnostics, Preclinical Research, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Veterinary Biomarkers Market is Projected to reach USD 1.5 Billion by 2028, at a CAGR of 11.7%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zoetis, Inc., Merck & Co., Inc., Virbac, IDEXX Laboratories, Inc., MI:RNA Diagnostics Ltd., Mercodia AB, Antech Diagnostics, Inc. (Mars, Inc.), Avacta Animal Health Limited (Vimian Group), Life Diagnostics, Inc., and Acuvet Biotech.
By Animal Type
By Disease Type
By Product Type
By Application
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 